a b s t r a c t a r t i c l e i n f o
Introduction
Production of self-reactive antibodies in the presence of tumor was first described 3 decades ago, and since the initial report, several dozen paraneoplastic autoantibodies have been identified [1] . Encephalitis due to production of autoantibodies in the presence of ovarian teratoma was reported in 1999 [2] and subsequently determined to be due to antibodies against the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor [3] . A later report documented the condition in patients free of teratoma and found that such patients may fare worse [4] . The anti-CD20 antibody rituximab has been used to successfully treat this condition [5] and has become the standard of care in refractory cases [6] . To our knowledge, autopsy findings from a patient who fails to respond to rituximab therapy have not previously been reported. In the present case, these findings demonstrate both ongoing autoantibody production and abundant plasma cells in lymphoid tissue, indicating both the need for aggressive therapy [7] and the potential utility of diagnostic biopsy.
Results
A young adult with a family history of lupus and a personal history of herpes simplex infection diagnosed 1 year earlier during the birth of a child developed tongue swelling, mouth sores, and headache. Approximately 3 months later, she would die from the condition. Her initial symptoms progressed to confusion, word-finding difficulties, and hallucinations, and then she suffered a seizure. She visited and was released from an outside hospital emergency department 2 times. Five days after symptoms began, she was admitted to an outside hospital with fluctuating mental status. One day after admission, cerebrospinal fluid (CSF), which showed 0 red blood cell/μL, 39 white blood cells/μL with 95% lymphs, protein of 24 mg/dL, and glucose of 70 mg/dL, was positive for anti-NMDA receptor (NMDAR) autoantibodies. She continued to have seizure-like activity despite treatment with multiple antiepileptic drugs. Cranial imaging studies were unremarkable. Magnetic resonance imaging of the pelvis was significant only for a small Gartner cyst. 
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Journal of Critical Care j o u r n a l h o m e p a g e : w w w . j c c j o u r n a l . o r g (HSV) testing of CSF by polymerase chain reaction and enzyme-linked immunosorbent assay showed a negative result, as did numerous other assays for infection. She received treatment with high-dose methylprednisolone, intravenous immunoglobulin, acyclovir, and rituximab, but did not improve. Four weeks after symptom onset, the patient was transferred to the intensive care unit at our institution, where electroencephalogram showed the "extreme delta brush" pattern characteristic of this entity. She received valacyclovir, prednisone, and 10 sessions of plasmapheresis without response. She had mandibular fracture due to facial dyskinesia as a result of ongoing seizures. Propofol was necessary for seizure control. Bilateral salpingo-oophorectomy was performed, but no evidence of teratoma was found and symptoms were unchanged. Repeated brain magnetic resonance imaging showed no definitive abnormality. Throughout her hospital course, she had marked fluctuations in heart rate, respiratory rate, and blood pressure. Ninety-three days after the patient's first symptoms, she was found unresponsive, and despite resuscitative efforts, she died, with autonomic instability as the presumptive proximate cause. A serum sample from 4 days before death was positive for antibody to NMDAR NR1 subunit.
At autopsy, the brain was grossly unremarkable. Microscopically, the hippocampus and adjacent medial temporal lobe demonstrated prominent elongated microglial nuclei apposed to intact pyramidal cells (Fig. 1A) . Immunohistochemical staining for Iba-1 confirmed the microglial identity of these cells and highlighted their processes encircling neuronal somata (Fig. 1B) . Immunohistochemical stain for CD3 demonstrated T cells scattered throughout the parenchyma (Fig. 1C) . High-power examination showed small numbers of T cells near pyramidal neurons and microglia (Fig. 1D) . However, neither in these inflamed areas nor elsewhere in the parenchyma, meninges, vessels, or Virchow-Robin or perivascular spaces of the cortex, basal ganglia, midbrain, cerebellum, brainstem, spinal cord, or eyes were plasma cells or lymphoid aggregates detected. The hippocampus and medial temporal lobes were sampled at 3 anteroposterior levels from both the right and left sides, and the thalamus, basal ganglia, and temporal lobe deep white matter were also sampled bilaterally. Immunohistochemical stains of selected brain areas for B cell and plasmablast/plasma cell markers CD20, CD19, and CD138 disclosed no cells (not shown).
Examination of a somatic lymph node demonstrated many cells with plasma cell morphology distributed along sinusoids, often in clusters (Fig. 1E) . Immunohistochemical stain for CD138 confirmed plasma cell identity (Fig. 1F ). Scattered cells with membranous staining for CD138 were also seen in the bone marrow (not shown), although these were less readily identified morphologically, perhaps reflecting decalcification. Such cells were not found in the spleen.
Discussion
The development after HSV encephalitis of syndromes characterized by anti-NMDAR autoantibodies [8] is important to consider in this patient with a history of mucocutaneous herpes simplex infection and no evidence of ovarian teratoma on microscopic examination, but the negative polymerase chain reaction and enzyme-linked immunosorbent assay studies for HSV suggest that it did not contribute. Given her positive antinuclear and anticardiolipin antibodies, family history of lupus, and initial presentation with mouth sores, the patient's encephalitis may have arisen in association with an underlying undiagnosed autoimmune disease. Alternatively, prior exposure to fetal tissue could have led to the development of anti-NMDAR autoantibodies.
Microglial activation and T cells encircling neurons are reported in "classic" paraneoplastic antibody-mediated encephalitides [9] . In patients with anti-NMDAR antibody encephalitis not treated with rituximab, perivascular lymphocyte aggregates can be pronounced, and these aggregates have been shown to harbor plasma cells [10, 11] . In the present case, no B cells, plasmablasts, or plasma cells were identified in any brain region. The absence of B cells reflects the use of rituximab, which can lower their numbers for up to 12 months [12] , whereas plasma cells are resistant to rituximab [13] .
Testing of serum for anti-NMDAR Ab is less sensitive than is testing of CSF, but highly specific, with no false positives reported in 100 cases [14] , so the serum test shortly before death confirms the presence of the auto-antibody. Rituximab treatment was effective, as demonstrated by the 2 very low measurements of circulating CD19 + cells.
The half-life of IgG, the most long-lived antibody, is approximately 20 days [15] . Thus, 70 days after rituximab, only 8.8% of the antibody would be expected to remain. As an alternative estimate, an older study found that at least 5% of IgG is turned over daily [16] , which would result in 2.8% of the original antibody molecules being present 70 days after rituximab treatment. In addition, the patient underwent 10 cycles of pheresis. Hence, the antibody molecules present in serum must have been produced after rituximab. Given the resistance of plasma cells to rituximab, the presence of anti-NR1 autoantibody in serum after rituximab and pheresis is most readily explained as continued antibody production by plasma cells that existed before the treatment. Refractory anti-NMDAR encephalitis can cause prolonged status epilepticus, which has a mortality rate of approximately 65% [17] . Autopsy indicates that despite the neurotropism of the anti-NMDAR autoantibody, the immunoprivileged central nervous system is not the site of production. Clusters of plasma cells are found adjacent to lymph node sinusoids and are the likely producers of these antibodies, making them the therapeutic target. Localization of plasma cells to lymph nodes by biopsy could facilitate elimination by cytotoxic therapy and be used to monitor response to such treatment or to targeted therapy such as interleukin 6 antagonism [18] . Better characterization through biopsy assessment could improve outcome in refractory cases as likely to be encountered in the critical care setting.
